The panel also called on Douglas Throckmorton, MD,, deputy director at the Food and Drug Administration’s Center for Drug Evaluation and Research, for answers regarding delays in the approval of a competing epinephrine auto-injector.
“There is justified outrage from families and schools across the country struggling to afford the high cost of EpiPens,” committee Chairman and Rep. Jason Chaffetz (R-Utah) and Rep. Elijah Cummings (D-Md.) said in a statement.
The Senate Permanent Select Subcommittee on Investigations has also opened a preliminary inquiry on Canonsburg, Pa.-based Mylan.
More articles on supply chain:
Market exclusivity main factor in high drug prices, study finds
Supply chain salaries to increase nearly 3% in 2017
5 myths about the EpiPen controversy
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
